Storys aus Lugano, Switzerland

15.10.2012 – 08:00
Helsinn Healthcare SA
Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)
Lugano, Switzerland and Melbourne, Australia (ots) - Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement for the innovative phase III ghrelin receptor agonist Melbourne biopharmaceutical company Specialised Therapeutics ...
mehr
01.10.2012 – 12:48
Helsinn Healthcare SA
Oral Palonosetron shows safe and effective control of nausea and vomiting induced by multiple cycles of chemotherapy
Lugano, Switzerland & Vienna, Austria (ots) - New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the chemotherapy cycles and a positive safety profile The oral formulation of palonosetron, the second generation 5-HT3 receptor ...
mehr
13.09.2012 – 15:18
Helsinn Healthcare SA
Helsinn Grants to DARA Exclusive U.S. Commercial Rights to Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis
Lugano, Switzerland / Raleigh, N.C., USA (ots) - Gelclair® Strengthens DARA's Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S. ...
mehr
16.07.2012 – 12:00
Helsinn Healthcare SA
Helsinn partners with the European School of Oncology (ESO)
Lugano, Switzerland (ots) - Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme Through its support to the Sharing Progress in Cancer Care (SPCC) Programme, Helsinn Group starts to actively collaborate with the European School of Oncology (ESO) in promoting education in oncology, with special attention to cancer supportive care. SPPC is a collaborative ...
mehr
23.09.2011 – 12:00
Helsinn Healthcare SA
Helsinn Group and Eisai Inc. announce start of phase III clinical program of oral fixed-dose combination of Netupitant/Palonosetron (300mg/0.50mg) for prevention of CINV
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...
mehr

Vorherige12

Storys aus Lugano, Switzerland

Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)

Oral Palonosetron shows safe and effective control of nausea and vomiting induced by multiple cycles of chemotherapy

Helsinn Grants to DARA Exclusive U.S. Commercial Rights to Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis

Helsinn partners with the European School of Oncology (ESO)

Helsinn Group and Eisai Inc. announce start of phase III clinical program of oral fixed-dose combination of Netupitant/Palonosetron (300mg/0.50mg) for prevention of CINV